Picture of Alimera Sciences logo

ALIM — Alimera Sciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Alimera Sciences Inc expected to post a loss of 33 cents a share - Earnings Preview

* Alimera Sciences Inc  ALIM.OQ   ALIM.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
22 (estimated). 
    * The Alpharetta Georgia-based  company is expected to
report  a
4.7% increase in revenue to $14.617 million from $13.96 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Alimera Sciences
Inc is
for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Alimera
Sciences
Inc is $9​, above​ its last closing price of $2.41. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.40       -0.40      -0.75     Missed  -86
 Jun. 30 2022  -0.55       -0.55      -0.45     Beat    18.7
 Mar. 31 2022  -0.69       -0.69      -0.85     Missed  -23.2​
 Dec. 31 2021  -0.41       -0.42      -0.59     Missed  -40.5
 ​​Sep.        -0.52       -0.52      -0.60     Missed  -14.3
 30 2021                                                
 Jun. 30 2021  1.05        1.06       0.72      Missed  -32.1​
 Mar. 31 2021  -0.52       -0.54      -0.63     Missed  -16.7
 Dec. 31 2020  -0.04       -0.04      -0.18     Missed  -315.4
 This summary was machine generated February 20 at 16:44 GMT. 
All figures in US dollars  unless otherwise stated

Recent news on Alimera Sciences

See all news